title: Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies.
abstract: Interleukin 4, a T cell-derived 20-kDa glycoprotein, plays an important role in regulating the immune response of B cells, T cells, and macrophages against infections and malignant cells. For this reason recombinant human interleukin 4 (rhIL-4) has entered early clinical trials in cancer patients. In the present study we report that rhIL-4 has an antiproliferative effect on five of nine cell lines derived from human colon tumors, head and neck tumors, and glioblastomas as measured by a decrease of colony formation in human tumor cloning assays. All of the cell lines with in vitro responsiveness express at least 100 high-affinity receptors for human interleukin 4 per cell on their cell surface, whereas the nonresponsive tumor cell lines lack expression of high-affinity receptors for human interleukin 4 on their cell surface. In the next series of experiments we have xenotransplanted some of the responsive cell lines into athymic nude mice. Subsequently, the animals were treated s.c. twice daily with 0.5 mg/m2 rhIL-4 or control vehicle for at least 12 days. There was a clear growth inhibition of these xenotransplanted tumors in the mice treated with rhIL-4. Histology of the tumors in both groups revealed no marked infiltration with murine hematopoietic and lymphocytic cells as evaluated by staining with a rat anti-mouse CD45 antibody. We conclude that rhIL-4 has a direct therapeutic activity on the growth of some human epithelial and nonepithelial tumor cell lines which, along with its regulatory function on hematolymphopoietic cells, makes this cytokine an interesting candidate for experimental tumor therapy.
authors.affiliation: Department of Hematology and Oncology, Klinikum Steglitz, Freie Universitaet Berlin, Germany.
authors.forename: M S
authors.initials: MS
authors.lastname: Topp
authors.forename: C A
authors.initials: CA
authors.lastname: Papadimitriou
authors.forename: F
authors.initials: F
authors.lastname: Eitelbach
authors.forename: M
authors.initials: M
authors.lastname: Koenigsmann
authors.forename: E
authors.initials: E
authors.lastname: Oelmann
authors.forename: B
authors.initials: B
authors.lastname: Koehler
authors.forename: D
authors.initials: D
authors.lastname: Oberberg
authors.forename: B
authors.initials: B
authors.lastname: Reufi
authors.forename: H
authors.initials: H
authors.lastname: Stein
authors.forename: E
authors.initials: E
authors.lastname: Thiel
mesh_terms: D000818:Animals; D003110:Colonic Neoplasms / Q000378:metabolism / Q000628:therapy; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005909:Glioblastoma / Q000378:metabolism / Q000628:therapy; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000628:therapy; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D011897:Random Allocation; D018123:Receptors, Interleukin / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D018123:Receptors, Interleukin; D011993:Recombinant Fusion Proteins; D015847:Interleukin-4